Core Viewpoint - The performance of four major flu vaccine companies in China is significantly lagging behind that of a single antiviral drug, Oseltamivir, highlighting challenges in flu vaccine promotion and public perception [1] Group 1: Company Performance - The main flu vaccine companies in A-shares include Hualan Biological (301207.SZ), Jindike (688670.SH), and Baike Biological (688276.SH), while the primary company in Hong Kong is Zhonghui Biological (02627.HK) [1] - From 2021 to 2024, Hualan Biological has maintained its leading position in the domestic flu vaccine market with consistent batch approvals [1] - The total sales revenue of the four flu vaccine companies in 2024 is projected to be less than 1.6 billion yuan [1] Group 2: Market Comparison - In contrast, Dongyang Sunshine Pharmaceutical (06887.HK), which holds the largest market share in China's antiviral drug market, is expected to achieve sales of approximately 2.6 billion yuan for Oseltamivir in 2024 [1] Group 3: Promotion Challenges - The promotion of flu vaccines faces significant hurdles due to public perceptions of necessity, concerns about vaccine efficacy, and fears of side effects [1] - Industry insiders indicate that the public has higher safety expectations for vaccines compared to antiviral drugs, leading to lower tolerance for potential side effects [1]